JPRN-jRCTs051180192
Completed
Phase 2
A phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in T3/T4a and/or lymph node-positive advanced adenocarcinoma of the esophagogastric junction. (ESOX trial) - ESOX trial
Watanabe Masayuki0 sites50 target enrollmentMarch 26, 2019
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- adenocarcinoma of the esophagogastric junction
- Sponsor
- Watanabe Masayuki
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Pathologically proven adenocarcinoma of the esophagus.
- •2\) Siewert type I or typeII with esophageal invasion over 3 cm.
- •3\) T3/T4a and/or lymph node\-positive (over 1cm )
- •4\) Eligible for surgery with curative intent.
- •5\) no prior therapy
- •6\) An age of over 20
- •7\) An ECOG performance status of 0 or 1
- •8\) Major organs are in normal conditions.
- •Hemoglobin \=\> 8\.0g/dL
- •neutrophil count \=\> 1,500/mm3
Exclusion Criteria
- •1\) Active synchronous or metachronous malignancy, excepting for early stage cancers
- •2\) Active infectious diseases
- •3\) Uncontrollable HBV infection
- •4\) Pregnant or lactation women, or women with the possibility of the pregnancy.
- •5\) Severe mental disorders, neurological disease
- •6\) under systemic steroid therapy
- •7\) under treatment of flucytosine, phenytoin or warfarin potassium
- •8\) Iodoallergy
- •9\) Unstable angina, or myocardial infarction within 6 months.
- •10\) Patients who are judged inappropriate for the entry into this study by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A phase II study of systemic chemotherapy with S-1 plus oxaliplatin followed by surgery in T3/T4a and/or lymph node-positive advanced adenocarcinoma of the esophagogastric junctioJPRN-UMIN000020815Cancer Institute Hospital, Gastroenterological Chemotherapy Department50
Completed
Phase 2
A phase II study of systemic chemotherapy with S-1 and Oxaliplatin followed by gastrectomy with D2 or D2 plus limited para-aortic lymph node dissection in HER2 negative advanced gastric or esophagogastric junction cancer with extensive lymph node metastasisGastric cancerJPRN-UMIN000027506Cancer Institute Hospital35
Active, not recruiting
Phase 2
SOX-D2 studyJPRN-jRCTs051180198Sano Takeshi35
Completed
Not Applicable
A phase I/II study of chemotherapy using S-1, Oxaliplatin plus Irinotecan for unresectable pancreatic cancerunresectable pancreatic cancerJPRN-UMIN000014471Department of Gastroenterology Kitasato University School of Medicine25
Recruiting
Phase 2
Phase II study of perioperative chemotherapy for cStage II and III thoracic esophageal cancerJPRN-jRCTs051200048Kitadani Junya27